Promising step forward for triple negative breast cancer treatment

Triple Negative Breast CancerCancer researchers in the UK have linked an overactive gene to a particularly aggressive type of breast cancer called “triple negative” breast cancer.

The team, from the Wellcome Trust Sanger Institute and the University of Cambridge, identified the gene called BCL11A as especially active in triple negative breast cancer, raising hope for those affected by this cancer type.

Prognosis for triple negative cancers is generally poorer than for other forms as there is limited knowledge of the distinct genetic properties of the disease, making the development of new treatments difficult.

Generally, therapies used in treating other breast cancer types, like tamoxifen, do not work on this type of cancer because triple negative tumour cells lack three of the different ‘receptor’ molecules that are targeted by the treatments.

Most triple-negative breast cancer tumours are of a genetic type called ‘basal-like’. BCL11A was found to be overactive in tumour samples from around eight in 10 patients with the ‘basal-like’ disease.

Dr Pentao Liu, senior author on the study, said BCL11A activity stood out as being particularly active in samples from triple negative cancers.

Dr Walid Khaled, co-author on the study said, “Our studies in human cells clearly marked BCL11A as a novel driver for triple-negative breast cancers.”

This discovery builds on researchers’ work to develop a broader understanding of breast cancer which will inform clinical decisions, treatment choices and finding new therapies.

For more information, please click here.

Manipulating molecules to enhance breast cancer treatment

funding research into breast cancerThe ACRF is proud to have funded a cutting-edge research discovery at Sydney’s Garvan Institute which revealed a known ‘transcription factor’ could be at the heart of many ineffective breast cancer treatments.

‘Transcription factors’ are molecules which act like a switch – turning genes on and off to change the behaviour and characteristics of our cells.

‘ELF5’ is one such transcription factor, best understood for its role in triggering oestrogen-receptor negative (ER-negative) cells for the development of breast milk during pregnancy.

But cancer researchers at the Garvan Institute of Medical Research have also shown that ELF5 can prevent breast cancer treatments from working.

In a preclinical study, Associate Professor Chris Ormandy and his team found that ELF5 can make an oestrogen-receptor positive (ER+) tumour cell behave like an ER- negative cell.  Continue reading “Manipulating molecules to enhance breast cancer treatment”